

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:  
MICHAEL R. KRAWZSENEK  
FULBRIGHT & JAWORSKI, LLP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TX 78701

# PCT

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing (day/month/year)	<b>13 MAY 2005</b>
-------------------------------------	--------------------

**FOR FURTHER ACTION**

See paragraph 2 below

Applicant's or agent's file reference

MESC:009WO

International application No.	International filing date (day/month/year)	Priority date (day/month/year)
PCT/US04/33255	08 October 2004 (08.10.2004)	08 October 2003 (08.10.2003)

International Patent Classification (IPC) or both national classification and IPC

IPC(7): C07F 9/02; C07C 327/00; A61K 31/265. and US Cl.: 558/70, 230; 514/512.

Applicant

MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

**2. FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

**3. For further details, see notes to Form PCT/ISA/220.**

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer  Robert Shiao Telephone No. (571)272-1600
--	---

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US04/33255

**Box No. I Basis of this opinion**

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.  
 This opinion has been established on the basis of a translation from the original language into the following language \_\_\_, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material  
 a sequence listing  
 table(s) related to the sequence listing
  - b. format of material  
 in written format  
 in computer readable form
  - c. time of filing/furnishing  
 contained in international application as filed.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority for the purposes of search.
3.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

<b>Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</b>	International application No. PCT/US04/33255
--	---

**1. Statement**

Novelty (N)	Claims <u>1-47</u>	YES
	Claims <u>NONE</u>	NO
Inventive step (IS)	Claims <u>1-47</u>	YES
	Claims <u>NONE</u>	NO
Industrial applicability (IA)	Claims <u>1-47</u>	YES
	Claims <u>NONE</u>	NO

**2. Citations and explanations:**

Claims 1-47 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest what the instant compounds are. This invention relates to site and pate selective prodrug of formulation of D609 with antioxidant and anticancer activity. The closest reference is Bai et al. publication, J. of Pharmacology and Experimenyal Therapeutics, 2004, 309(3), pages 1051-1059, discloses prodrug Modification Increase Potassium Tricyclo[5.2.1.0]-decan-8-yl Dithiocarbonate (D609) Chemical Stability and Cytotoxicity against U937 Leukemia Cells. Suggestion for modification of above reference to obtain the instant compound/compositions and methods of use, has not been found.

Claims 1-47 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.